After 66 children in the Gambia died after eating cough syrup made in India, the pharmaceutical business Maiden Pharmaceuticals has come under scrutiny.
On Saturday, Maiden Pharmaceuticals, an Indian pharmaceutical business, expressed dismay over media reports claiming 66 Gambian children died after ingesting its cough medicine.
Read Also: World Mental Health Day 2022 – Theme, background, significance, and other information
Pharmaceutical company told ANI exclusively :-
The pharmaceutical company told ANI exclusively that it was “shocked to hear the media reports regarding the deaths and deeply saddened on this incident,” but added that “we received the official information from our agent in the Gambia on October 5, 2022, and on the following date, World Health Organization alert was issued against us.”
After 66 children in the Gambia died after ingesting cough medication made in India, the pharmaceutical business Maiden Pharmaceuticals has come under scrutiny.
The company’s director, Vivek Goyal, issued a formal statement in which he stated, “We have been in the pharmaceutical business for more than three decades and have diligently followed the guidelines of the health officials, including the Drugs Controller General (India) and the State Drugs Controllers, Haryana.
He added that his business does not sell anything on the domestic market because it has legal drug clearances for export. He further stated that his company only buys raw resources from reputable, accredited businesses.
Read Also: Learn about business and startup news in Pune | Financepeer
Central Drugs Standard Control Organisation (CDSCO) :-
The samples were drawn by the Central Drugs Standard Control Organisation (CDSCO) along with all pertinent documents in issue in front of our directors, Goyal said in the statement. “The government authorities inspected our company on October 1 and October 3, October 6, and 7,” Goyal said.
Following a WHO medical alert, the drug authorities have taken samples of cold and cough medicine from Maiden Pharmaceutical’s Sonipat manufacturing site. Results are expected soon.
Since the situation is still under investigation and in court, we are awaiting the results of the samples that CDSCO officials took. We regret that we are unable to comment on any further matters, but we will keep you updated as we learn more in the future.
The four cough and cold syrups made by Maiden Pharmaceuticals in India were the subject of a notice from the WHO on Wednesday. The same cough and cold medications may be to blame for 66 children’s deaths in Gambia, according to a WHO alert.
According to sources, it has been established through the preliminary investigation that Maiden Pharmaceutical Limited, Sonipat, Haryana, is a manufacturer licenced by the State Drug Controller for the items in question and holds production authorisation for these products. So yet, the company has only produced and exported these goods to the Gambia.
